Connection

MICHAEL ITTMANN to Mice

This is a "connection" page, showing publications MICHAEL ITTMANN has written about Mice.
Connection Strength

1.180
  1. MEX3D is an oncogenic driver in prostate cancer. Prostate. 2021 11; 81(15):1202-1213.
    View in: PubMed
    Score: 0.052
  2. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020 01; 80(1):65-73.
    View in: PubMed
    Score: 0.046
  3. Anatomy and Histology of the Human and Murine Prostate. Cold Spring Harb Perspect Med. 2018 05 01; 8(5).
    View in: PubMed
    Score: 0.042
  4. RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res. 2017 08 15; 77(16):4247-4257.
    View in: PubMed
    Score: 0.039
  5. MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer. Cancer Res. 2016 11 01; 76(21):6290-6298.
    View in: PubMed
    Score: 0.037
  6. FGF23 promotes prostate cancer progression. Oncotarget. 2015 Jul 10; 6(19):17291-301.
    View in: PubMed
    Score: 0.034
  7. The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. Am J Pathol. 2014 Mar; 184(3):721-31.
    View in: PubMed
    Score: 0.031
  8. Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res. 2014 Jan 01; 20(1):100-9.
    View in: PubMed
    Score: 0.030
  9. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013 May 01; 73(9):2718-36.
    View in: PubMed
    Score: 0.029
  10. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 2013 Apr 15; 73(8):2551-62.
    View in: PubMed
    Score: 0.029
  11. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.
    View in: PubMed
    Score: 0.028
  12. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res. 2012 Jul 15; 18(14):3880-8.
    View in: PubMed
    Score: 0.027
  13. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008 Oct 15; 68(20):8516-24.
    View in: PubMed
    Score: 0.021
  14. Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy. J Control Release. 2026 07 10; 395:115004.
    View in: PubMed
    Score: 0.018
  15. Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Rep. 2025 Jun 24; 44(6):115792.
    View in: PubMed
    Score: 0.017
  16. Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. Cancer Res. 2024 03 04; 84(5):703-724.
    View in: PubMed
    Score: 0.016
  17. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 2003 Sep 15; 63(18):5754-60.
    View in: PubMed
    Score: 0.015
  18. Persistent organic pollutants promote aggressiveness in prostate cancer. Oncogene. 2023 09; 42(38):2854-2867.
    View in: PubMed
    Score: 0.015
  19. SMAD2/3 signaling in the uterine epithelium controls endometrial cell homeostasis and regeneration. Commun Biol. 2023 03 11; 6(1):261.
    View in: PubMed
    Score: 0.015
  20. Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus. Cytokine. 2022 12; 160:156022.
    View in: PubMed
    Score: 0.014
  21. Systemic Ablation of Camkk2 Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer. Cells. 2022 06 10; 11(12).
    View in: PubMed
    Score: 0.014
  22. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021 11; 23(11):1147-1165.
    View in: PubMed
    Score: 0.013
  23. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11563-8.
    View in: PubMed
    Score: 0.013
  24. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021 11 01; 520:344-360.
    View in: PubMed
    Score: 0.013
  25. INPP4B protects from metabolic?syndrome and associated disorders. Commun Biol. 2021 03 26; 4(1):416.
    View in: PubMed
    Score: 0.013
  26. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 2021 02 15; 131(4).
    View in: PubMed
    Score: 0.013
  27. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene. 2021 03; 40(9):1690-1705.
    View in: PubMed
    Score: 0.013
  28. Absence of PTEN/MMAC1 pseudogene in mice. DNA Cell Biol. 2000 May; 19(5):301-5.
    View in: PubMed
    Score: 0.012
  29. Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland. Cytokine. 2019 11; 123:154745.
    View in: PubMed
    Score: 0.011
  30. JNK1/2 represses Lkb1-deficiency-induced lung squamous cell carcinoma progression. Nat Commun. 2019 05 14; 10(1):2148.
    View in: PubMed
    Score: 0.011
  31. Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms. Cell Stem Cell. 2019 05 02; 24(5):753-768.e6.
    View in: PubMed
    Score: 0.011
  32. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019 01; 1(1):70-85.
    View in: PubMed
    Score: 0.011
  33. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest. 2018 07 02; 128(7):3129-3143.
    View in: PubMed
    Score: 0.010
  34. Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
    View in: PubMed
    Score: 0.010
  35. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017 10 09; 32(4):474-489.e6.
    View in: PubMed
    Score: 0.010
  36. A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis. Neoplasia. 2017 May; 19(5):421-428.
    View in: PubMed
    Score: 0.010
  37. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Oncogene. 2017 08 17; 36(33):4767-4777.
    View in: PubMed
    Score: 0.010
  38. SPOP Mutation Drives Prostate Tumorigenesis In?Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell. 2017 03 13; 31(3):436-451.
    View in: PubMed
    Score: 0.010
  39. CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun. 2016 11 21; 7:13362.
    View in: PubMed
    Score: 0.009
  40. Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. Mol Cell. 2016 09 15; 63(6):976-89.
    View in: PubMed
    Score: 0.009
  41. The essential role of GATA transcription factors in adult murine prostate. Oncotarget. 2016 Jul 26; 7(30):47891-47903.
    View in: PubMed
    Score: 0.009
  42. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget. 2016 Jul 19; 7(29):45171-45185.
    View in: PubMed
    Score: 0.009
  43. Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. Oncogene. 2017 02 02; 36(5):618-627.
    View in: PubMed
    Score: 0.009
  44. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. Oncotarget. 2016 Jun 21; 7(25):37993-38003.
    View in: PubMed
    Score: 0.009
  45. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest. 2016 07 01; 126(7):2626-41.
    View in: PubMed
    Score: 0.009
  46. The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker. Prostate. 2016 10; 76(14):1271-84.
    View in: PubMed
    Score: 0.009
  47. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016 05 19; 7:11612.
    View in: PubMed
    Score: 0.009
  48. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun. 2016 04 25; 7:11418.
    View in: PubMed
    Score: 0.009
  49. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.009
  50. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. 2016 11 17; 35(46):5963-5976.
    View in: PubMed
    Score: 0.009
  51. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun. 2016 Jan 25; 7:10500.
    View in: PubMed
    Score: 0.009
  52. Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One. 2015; 10(6):e0128467.
    View in: PubMed
    Score: 0.008
  53. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015 May; 21(5):524-9.
    View in: PubMed
    Score: 0.008
  54. Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. Oncotarget. 2015 Mar 20; 6(8):6281-94.
    View in: PubMed
    Score: 0.008
  55. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. Horm Cancer. 2015 Jun; 6(2-3):67-86.
    View in: PubMed
    Score: 0.008
  56. Cell cycle control of the BN51 cell cycle gene which encodes a subunit of RNA polymerase III. Cell Growth Differ. 1994 Jul; 5(7):783-8.
    View in: PubMed
    Score: 0.008
  57. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology. 2014 Sep; 155(9):3262-73.
    View in: PubMed
    Score: 0.008
  58. Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis. Am J Pathol. 2014 Jun; 184(6):1860-70.
    View in: PubMed
    Score: 0.008
  59. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A. 2014 Feb 04; 111(5):E592-600.
    View in: PubMed
    Score: 0.008
  60. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 2014 Feb 15; 20(4):962-71.
    View in: PubMed
    Score: 0.008
  61. FGFR1-WNT-TGF-? signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res. 2014 Jan 15; 74(2):609-20.
    View in: PubMed
    Score: 0.008
  62. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene. 2014 Jun 12; 33(24):3099-108.
    View in: PubMed
    Score: 0.007
  63. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res. 2013 Jul 01; 73(13):3997-4008.
    View in: PubMed
    Score: 0.007
  64. SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer. Mol Endocrinol. 2013 Jun; 27(6):925-39.
    View in: PubMed
    Score: 0.007
  65. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013 Jun 15; 73(12):3716-24.
    View in: PubMed
    Score: 0.007
  66. ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res. 2013 Jul; 11(7):736-47.
    View in: PubMed
    Score: 0.007
  67. COUP-TFII inhibits TGF-?-induced growth barrier to promote prostate tumorigenesis. Nature. 2013 Jan 10; 493(7431):236-40.
    View in: PubMed
    Score: 0.007
  68. Notch and TGF? form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. Cell Stem Cell. 2012 Nov 02; 11(5):676-88.
    View in: PubMed
    Score: 0.007
  69. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell. 2012 Feb 14; 21(2):253-65.
    View in: PubMed
    Score: 0.007
  70. Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. PLoS One. 2012; 7(1):e30814.
    View in: PubMed
    Score: 0.007
  71. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. Cancer Res. 2011 Dec 15; 71(24):7694-704.
    View in: PubMed
    Score: 0.007
  72. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol. 2011 Apr 15; 6:39.
    View in: PubMed
    Score: 0.006
  73. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.006
  74. TGF-?1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse. PLoS One. 2010 Oct 29; 5(10):e13751.
    View in: PubMed
    Score: 0.006
  75. Dicer ablation impairs prostate stem cell activity and causes prostate atrophy. Stem Cells. 2010 Jul; 28(7):1260-9.
    View in: PubMed
    Score: 0.006
  76. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem. 2010 Aug 13; 285(33):25859-66.
    View in: PubMed
    Score: 0.006
  77. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.
    View in: PubMed
    Score: 0.006
  78. GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression. Cancer Res. 2009 Feb 01; 69(3):819-27.
    View in: PubMed
    Score: 0.005
  79. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer. 2008 Aug 01; 123(3):543-51.
    View in: PubMed
    Score: 0.005
  80. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007 Dec; 12(6):559-71.
    View in: PubMed
    Score: 0.005
  81. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol. 2007 Oct; 178(4 Pt 1):1521-7.
    View in: PubMed
    Score: 0.005
  82. Oxygen tension directs chondrogenic differentiation of myelo-monocytic progenitors during endochondral bone formation. Tissue Eng. 2007 Aug; 13(8):2011-9.
    View in: PubMed
    Score: 0.005
  83. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
    View in: PubMed
    Score: 0.005
  84. Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol. 2007 Feb; 170(2):620-32.
    View in: PubMed
    Score: 0.005
  85. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 2006 Nov 15; 66(22):11039-46.
    View in: PubMed
    Score: 0.005
  86. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol. 2007 Feb; 38(2):299-307.
    View in: PubMed
    Score: 0.005
  87. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 2006 May 15; 66(10):5159-64.
    View in: PubMed
    Score: 0.005
  88. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate. 2006 Mar 01; 66(4):369-76.
    View in: PubMed
    Score: 0.004
  89. Bystin in perineural invasion of prostate cancer. Prostate. 2006 Feb 15; 66(3):266-72.
    View in: PubMed
    Score: 0.004
  90. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005 Sep 01; 65(17):7976-83.
    View in: PubMed
    Score: 0.004
  91. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A. 2005 Jan 25; 102(4):1151-6.
    View in: PubMed
    Score: 0.004
  92. Enhancement of both cellular and humoral responses to genetic immunization by co-administration of an antigen-expressing plasmid and a plasmid encoding the pro-apoptotic protein Bax. J Gene Med. 2004 Apr; 6(4):445-54.
    View in: PubMed
    Score: 0.004
  93. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004 Mar 15; 64(6):2270-305.
    View in: PubMed
    Score: 0.004
  94. Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate. 2004 Jan 01; 58(1):1-12.
    View in: PubMed
    Score: 0.004
  95. Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res. 2003 Dec 15; 63(24):8784-90.
    View in: PubMed
    Score: 0.004
  96. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 2003 Dec 01; 63(23):8256-63.
    View in: PubMed
    Score: 0.004
  97. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res. 2003 Oct 01; 63(19):6237-43.
    View in: PubMed
    Score: 0.004
  98. In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor. Prostate. 2003 Sep 15; 57(1):1-7.
    View in: PubMed
    Score: 0.004
  99. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003 May 15; 55(3):219-37.
    View in: PubMed
    Score: 0.004
  100. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther. 2002 Sep; 6(3):342-8.
    View in: PubMed
    Score: 0.004
  101. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001 May 15; 61(10):3882-5.
    View in: PubMed
    Score: 0.003
  102. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci U S A. 1998 May 12; 95(10):5672-7.
    View in: PubMed
    Score: 0.003
  103. A retrovirus carrying the K-fgf oncogene induces diffuse meningeal tumors and soft-tissue fibrosarcomas. Mol Cell Biol. 1993 Apr; 13(4):1998-2010.
    View in: PubMed
    Score: 0.002
  104. Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor. Proc Natl Acad Sci U S A. 1990 Jun; 87(11):4222-5.
    View in: PubMed
    Score: 0.001
  105. An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell. 1987 Aug 28; 50(5):729-37.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.